SoCal Bioinformatics Inc.

The submission represents a valid bioinformatics and proteomics B2B service, but the evaluation is severely undermined by heavily exaggerated and nonsensical claims. The submitter states the target audience is 'everyone' and claims 'most people have used my product,' which are impossible for a highly specialized clinical and pharmacogenomics firm. While the underlying industry holds high technical innovation and market relevance, the contradictory traction metrics ($500k all-time market cap for a 30-person team operating since 2016) and lack of response clarity result in the lowest possible quality multipliers across the board.